Pipeline
Rigorous and groundbreaking science has always been at the core of what we do at Genentech. Our R&D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics.
These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.
Anti-latent TGF-beta1 (SOF10)
Solid tumors
Solid tumors
Oncology
AR degrader
Metastatic castration-resistant prostate cancer (mCRPC)
Metastatic castration-resistant prostate cancer (mCRPC)
Oncology
Astegolimab
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Immunology
Atezolizumab
Previously untreated metastatic triple negative breast cancer (IMpassion132)
Previously untreated metastatic triple negative breast cancer (IMpassion132)
Oncology
Atezolizumab
Neoadjuvant triple negative breast cancer (IMpassion031)
Neoadjuvant triple negative breast cancer (IMpassion031)
Oncology
Atezolizumab
Adjuvant triple negative breast cancer (IMpassion030)
Adjuvant triple negative breast cancer (IMpassion030)
Oncology
Autogene cevumeran
Solid tumors
Solid tumors
Oncology
Autogene cevumeran
Advanced melanoma
Advanced melanoma
Oncology
Autogene cevumeran
Adjuvant pancreatic ductal adenocarcinoma (PDAC)
Adjuvant pancreatic ductal adenocarcinoma (PDAC)
Oncology
Baloxavir marboxil
Influenza in children ages 1 and older
Influenza in children ages 1 and older
Infectious Disease
Baloxavir marboxil
Reduction of transmission of influenza in households
Reduction of transmission of influenza in households
Infectious Disease
Cevostamab
Relapsed or refractory multiple myeloma
Relapsed or refractory multiple myeloma
Oncology
Cobimetinib
Metastatic melanoma
Metastatic melanoma
Oncology
Crovalimab
Paroxysmal nocturnal hemoglobinuria (PNH)
Paroxysmal nocturnal hemoglobinuria (PNH)
Other
Delandistrogene Moxeparvovec (SRP-9001)
Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Neuroscience
Englumafusp alfa (RG6076)
Heme tumors
Heme tumors
Oncology
Entrectinib
Non-small cell lung cancer
Non-small cell lung cancer
Oncology
Fenebrutinib
Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Neuroscience
Fenebrutinib
Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis
Neuroscience
Gazyva
Systemic lupus erythematosus
Systemic lupus erythematosus
Immunology
Giredestrant
Grade 1 endometrioid endometrial cancer
Grade 1 endometrioid endometrial cancer
Oncology
Giredestrant
ER+ HER2-negative breast cancer, adjuvant ER+ breast cancer
ER+ HER2-negative breast cancer, adjuvant ER+ breast cancer
Oncology
Giredestrant
1L ER+ metatstatic breast cancer
1L ER+ metatstatic breast cancer
Oncology
Glofitamab
R/R mantle cell lymphoma
R/R mantle cell lymphoma
Oncology
Glofitamab
1L diffuse large B-cell lymphoma
1L diffuse large B-cell lymphoma
Oncology
Glofitamab
2L+ diffuse large B-cell lymphoma
2L+ diffuse large B-cell lymphoma
Oncology
Inavolisib (GDC-0077)
HR+, HER2-negative, PIK3CA mutated mBC post CDK4/6i therapy (INAVO121)
HR+, HER2-negative, PIK3CA mutated mBC post CDK4/6i therapy (INAVO121)
Oncology
Inavolisib (GDC-0077)
Solid tumors and ER+ HER2-negative breast cancer
Solid tumors and ER+ HER2-negative breast cancer
Oncology
Inavolisib (GDC-0077)
PIK3CA-mutant HR+ mBC in combination with palbociclib fulvestrant
PIK3CA-mutant HR+ mBC in combination with palbociclib fulvestrant
Oncology
IONIS-FB-LRx
Geographic Atrophy (GA)
Geographic Atrophy (GA)
Ophthalmology
KRAS G12C (GDC-6036)
Metastatic solid tumors with KRAS G12C mutation
Metastatic solid tumors with KRAS G12C mutation
Oncology
Mosunetuzumab
2L+ follicular lymphoma
2L+ follicular lymphoma
Oncology
Mosunetuzumab
2L+ diffuse large B-cell lymphoma
2L+ diffuse large B-cell lymphoma
Oncology
Mosunetuzumab
Systemic lupus erythematosus
Systemic lupus erythematosus
Immunology
Obinutuzumab
Systemic lupus erythematosus
Systemic lupus erythematosus
Immunology
Obinutuzumab
Lupus nephritis
Lupus nephritis
Immunology
Pertuzumab
Early HER2-positive breast cancer in combination with trastuzumab emtansine
Early HER2-positive breast cancer in combination with trastuzumab emtansine
Oncology
Pertuzumab
Early and metastatic HER2-positive breast cancer in combination with atezolizumab
Early and metastatic HER2-positive breast cancer in combination with atezolizumab
Oncology
Port Delivery System with ranibizumab
Diabetic Macular Edema (DME)
Diabetic Macular Edema (DME)
Ophthalmology
Port Delivery System with ranibizumab
Diabetic Retinopathy without DME
Diabetic Retinopathy without DME
Ophthalmology
Prasinezumab
Parkinson’s disease
Parkinson’s disease
Neuroscience
RG6035 BrainShuttleTM CD20
Multiple Sclerosis
Multiple Sclerosis
Neuroscience
RG6120 (VEGF-Ang2 DutaFab)
wet age-related macular degeneration (AMD)
wet age-related macular degeneration (AMD)
Ophthalmology
RG6163
Psychiatric disorders
Psychiatric disorders
Neuroscience
RG6179
Diabetic Macular Edema (DME)
Diabetic Macular Edema (DME)
Ophthalmology
RG6179
Uveitic Macular Edema (UME)
Uveitic Macular Edema (UME)
Ophthalmology
RG6182
Neurodegenerative diseases
Neurodegenerative diseases
Neuroscience
RG6237
Neuromuscular disorders
Neuromuscular disorders
Neuroscience
RG6287
Acute graft versus host disease (aGVHD)
Acute graft versus host disease (aGVHD)
Immunology
RG6289
Alzheimer's Disease
Alzheimer's Disease
Neuroscience
RG6315
Immunologic Disorders
Immunologic Disorders
Immunology
Retinal Disease
Ophthalmology
RG6421
Muco-obstructive respiratory disease
Muco-obstructive respiratory disease
Immunology
RG6436
Complicated urinary tract infection
Complicated urinary tract infection
Infectious Disease
RG6501 (OpRegen)
Geographic Atrophy (GA)
Geographic Atrophy (GA)
Ophthalmology
RG6536 (Vixarelimab)
Idiopathic pulmonary fibrosis / Systemic sclerosis-associated interstitial lung disease (IPF & SSc-ILD)
Idiopathic pulmonary fibrosis / Systemic sclerosis-associated interstitial lung disease (IPF & SSc-ILD)
Immunology
RG6620
Solid tumors with KRAS G12D mutations
Solid tumors with KRAS G12D mutations
Oncology
RG7774
Diabetic Retinopathy
Diabetic Retinopathy
Ophthalmology
RG7921
wet age-related macular degeneration (AMD)
wet age-related macular degeneration (AMD)
Ophthalmology
rhPentraxin-2
Myelofibrosis
Myelofibrosis
Infectious Disease
tenecteplase
acute ischemic stroke (AIS)
acute ischemic stroke (AIS)
Neuroscience
Tiragolumab
Non-small cell lung cancer
Non-small cell lung cancer
Oncology
Tiragolumab
Esophageal cancer
Esophageal cancer
Oncology
Tiragolumab
Squamous cell carcinoma of head and neck
Squamous cell carcinoma of head and neck
Oncology
Tominersen
Early / Prodromal Huntington’s disease
Early / Prodromal Huntington’s disease
Neuroscience
Trastuzumab emtansine
1st line HER2-positive metastatic breast cancer
1st line HER2-positive metastatic breast cancer
Oncology
Trastuzumab emtansine
Early HER2-positive breast cancer in combination with pertuzumab
Early HER2-positive breast cancer in combination with pertuzumab
Oncology
Trastuzumab emtansine
Early and metastatic HER2-positive breast cancer in combination with atezolizumab
Early and metastatic HER2-positive breast cancer in combination with atezolizumab
Oncology
Trastuzumab emtansine
3rd line HER2-positive metastatic breast cancer
3rd line HER2-positive metastatic breast cancer
Oncology
Trastuzumab emtansine
2L + HER-2+ PD-L1+ mBC (KATE3)
2L + HER-2+ PD-L1+ mBC (KATE3)
Oncology
Trastuzumab emtansine
HER2-positive early breast cancer high-risk patients (ASTEFANIA)
HER2-positive early breast cancer high-risk patients (ASTEFANIA)
Oncology
trontinemab
Alzheimer’s disease
Alzheimer’s disease
Neuroscience
Vemurafenib
Papillary thyroid cancer, BRAF mutation positive
Papillary thyroid cancer, BRAF mutation positive
Oncology
Venetoclax
1L chronic lymphocytic leukemia
1L chronic lymphocytic leukemia
Oncology
Venetoclax
1L myelodysplastic syndromes
1L myelodysplastic syndromes
Oncology
Vismodegib
Operable basal cell carcinoma
Operable basal cell carcinoma
Oncology